高血压疾病中的金属蛋白酶 (MMP):作用,功能,药理学以及减轻病理生理变化的潜在策略
Soroush Taherkhani1, Mohammad Sheibani2,3, Ali Mohammadkhanizadeh1
1Department of Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Frontiers in pharmacology
|June 10, 2025
概括
矩阵金属蛋白酶 (MMPs) 通过重塑细胞外矩阵,有助于高血压相关的器官损伤. 向MMP可能会恢复平衡并改善高血压患者的心血管和结局.
科学领域:
- 生物化学 生物化学
- 心血管生物学 心血管生物学
- 病理生理学 病理生理学
背景情况:
- 矩阵金属蛋白酶 (MMPs) 是对细胞外矩阵 (ECM) 重塑至关重要的酶.
- 它们的失调与高血压介导的器官损伤有关,影响血管,心脏和系统.
- 在高血压中观察到MMPs (例如,MMP-1,MMP-3,MMP-9) 的升高,与血管功能障碍有关.
研究的目的:
- 阐明MMPs在高血压疾病病理生理学的作用.
- 了解MMPs为高血压中介的器官损伤做出贡献的机制.
- 探索MMP作为高血压并发症的潜在治疗点.
主要方法:
- 对高血压中MMP药物的文献综述.
- 对MMP参与ECM重塑和血管功能障碍的分析.
- 调查引发MMP激活和与TIMPs失衡的因素.
主要成果:
- 高血压导致MMP水平升高和激活,由氧化应激,炎症和血管激素II驱动.
- 在MMPs和组织金属蛋白酶抑制剂 (TIMPs) 之间的不平衡促进了过度的ECM降解.
- 这有助于血管光滑肌细胞的病理变化,促进合成表型和血管重塑.
结论:
- 通过ECM重塑,MMP在高血压相关的血管和器官损伤中发挥着重要作用.
- 在MMPs和TIMPs之间的不平衡是驱动病理变化的关键机制.
- 针对MMP提供了一个有希望的治疗策略,以减轻高血压并发症并改善患者的治疗结果.
相关概念视频
01:29Hypertension II: Pathophysiology
2
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
2
01:23Role of Matrix Metalloproteases in Degradation of ECM
2.3K
Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
2.3K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
395
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
395
01:18Hypertension and Regulation of Blood Pressure
1.9K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.9K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
490
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
490
01:23Antihypertensive Drugs: Vasodilators
490
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
490